Company Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.06 ^USD	+0.68%		-14.66%	-27.00%

Apr. 11	Zentalis Pharmaceuticals, Inc. Announces Executive Changes	CI
Apr. 11	Zentalis Pharmaceuticals, Inc. Announces CFO Changes	CI

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Companyâs lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Number of employees: 124

Managers	Title	Age	Since
Kimberly Blackwell CEO	Chief Executive Officer	55	20-06-30
Cam Gallagher FOU	Founder	54	14-12-22
Mark Lackner CTO	Chief Tech/Sci/R&D Officer	56	22-10-16
Diana Hausman CTO	Chief Tech/Sci/R&D Officer	61	23-05-07
Kyle Rasbach IRC	Investor Relations Contact	-	Jan. 18
Kimberly Freeman PRN	Corporate Officer/Principal	-	23-07-31
Alexandra Roy		-	-
Andrea Paul LAW	General Counsel	43	22-07-31
Meena Rao LAW	General Counsel	-	-
Dimitris Voliotis PRN	Corporate Officer/Principal	61	20-02-29

Members of the board	Title	Age	Since
Cam Gallagher FOU	Founder	54	14-12-22
Diana Hausman CTO	Chief Tech/Sci/R&D Officer	61	23-05-07
Karan Takhar BRD	Director/Board Member	32	17-11-30
Jan Skvarka BRD	Director/Board Member	57	22-09-11
Enoch K. Kariuki BRD	Director/Board Member	42	21-02-08
David Johnson CHM	Chairman	59	20-01-08
Kimberly Blackwell CEO	Chief Executive Officer	55	20-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	70,960,165	67,928,897 ( 95.73 %)	0	95.73 %

Name	Equities	%	Valuation
Matrix Capital Management Co. LP 19.67 %	13,959,973	19.67 %	220 M $
Eventide Asset Management LLC 16.29 %	11,559,975	16.29 %	182 M $
Fidelity Management & Research Co. LLC 14.57 %	10,336,971	14.57 %	163 M $
Vanguard Fiduciary Trust Co. 7.540 %	5,350,458	7.540 %	84 M $
BlackRock Advisors LLC 6.265 %	4,445,845	6.265 %	70 M $
STATE STREET CORPORATION 6.225 %	4,417,056	6.225 %	70 M $
Citadel Securities GP LLC 5.189 %	3,681,782	5.189 %	58 M $
T. Rowe Price International Ltd. 4.093 %	2,904,065	4.093 %	46 M $
Capital Research & Management Co. (International Investors) 3.974 %	2,819,664	3.974 %	44 M $
T. Rowe Price Investment Management, Inc. 3.300 %	2,341,783	3.300 %	37 M $

Zentalis Pharmaceuticals, Inc.

1359 Broadway Suite 801

10018, New York

http://www.zentalis.com

address Zentalis Pharmaceuticals, Inc.(ZNTL)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.06 USD

Average target price

35.6 USD

Spread / Average Target

+221.88%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ZENTALIS PHARMACEUTICALS, INC.	-27.00%	779M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs